Evidence map›Paper›PMID 41256693›Full record

ArticlebioRxiv : the preprint server for biology2025

Targeting a macrophage stemness factor to mitigate diseases post respiratory viral infection.

Mohd Arish, Arka Sen Chaudhuri, Janli Tang, Harish Narasimhan, An Fang, Jinyi Tang, Xiaoqin Wei, Chaofan Li, In Su Cheon, Wei Qian and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mohd ArishBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Arka Sen ChaudhuriBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Janli TangBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Harish NarasimhanBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
An FangBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Jinyi TangBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Xiaoqin WeiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Chaofan LiBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
In Su CheonBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Wei QianBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Farha NazDivision of Infectious Disease and International Health, Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Gislane Almeida-SantosBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Samuel Patrick YoungBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.
Tanyalak ParimonWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Yun Michael ShimDivision of Pulmonary Medicine and Critical Care Medicine, Department of Medicine, University of Virginia; Charlottesville, VA 22908, USA.
Robert VassalloDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic; Rochester, MN 55905, USA.
Peter ChenWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jie SunBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0002-2347-4511

Funding

Role of Surfactant Proteins in Mediating Noninfectious Inflammatory and FibroproP01HL108793 · NHLBI · DUKE UNIVERSITY · PI STRIPP, BARRY R · 2012 to 2022
$21.3M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
Host cellular network governing the development of post SARS-CoV-2 tissue sequelaeR01AI147394 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$4.7M
Molecular regulation of protective CD8 immunity against influenza infectionR01AI112844 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2015 to 2024
$4.5M
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeuticsR01HL132177 · NHLBI · UNIVERSITY OF VIRGINIA · PI QING, KUN, SHIM, YUN MICHAEL · 2017 to 2021
$3.9M
Elucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infectionR01AG069264 · NIA · UNIVERSITY OF VIRGINIA · PI Jie Sun · 2020 to 2026
$3.5M
Sexual dimorphism in susceptibility to emphysematous tissue injuryR01HL167202 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANI Wang MANICHAIKUL, Yun Michael Shim · 2023 to 2026
$3.0M
Roles of tissue-resident helper T cells in mucosal immunity against influenzainfectionR01AI154598 · NIAID · UNIVERSITY OF VIRGINIA · PI SUN, JIE · 2020 to 2024
$2.9M
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with AsthmaR01AI176171 · NIAID · UNIVERSITY OF VIRGINIA · PI Jie Sun, WILLIAM GERALD TEAGUE · 2023 to 2026
$2.7M
Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19R01HL170961 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jie Sun, ROBERT VASSALLO · 2023 to 2026
$2.7M
Syndecan-1 suppression of lung inflammation - Diversity SupplementR01HL159953 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHEN, PETER · 2022 to 2025
$2.7M
Discovery of New Anti-Inflammatory Agents to Treat COPDR01HL132287 · NHLBI · GEORGE MASON UNIVERSITY · PI NOBLE, SCHROEDER M, PAIGE, MIKELL · 2016 to 2019
$2.4M
NHLBI NIH HHS F31 HL170746NHLBI NIH HHS P01 HL108793NHLBI NIH HHS R01 HL132177NHLBI NIH HHS R01 HL132287NHLBI NIH HHS R01 HL152293NHLBI NIH HHS R01 HL155759NHLBI NIH HHS R01 HL159675NHLBI NIH HHS R01 HL159953NHLBI NIH HHS R01 HL167202NHLBI NIH HHS R01 HL170961NIAID NIH HHS R01 AI112844NIAID NIH HHS R01 AI147394NIAID NIH HHS R01 AI154598NIAID NIH HHS R01 AI176171NIAID NIH HHS R21 AI163753NIAID NIH HHS T32 AI007496NIA NIH HHS R01 AG069264
6 · The paper itself

Abstract

Tissue-resident alveolar macrophages (AMs) rely on intrinsic stem-like programs for self-renewal and maintenance, yet the transcriptional networks that support these functions and their relevance to post-viral lung disease remain largely unknown. Here, we identify TCF4 (

Identifiers

PMID41256693
PMCPMC12621715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.